Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism: The COBRRA Trial

ACCP EM PRN: April 2026Article: https://pubmed.ncbi.nlm.nih.gov/41812192/Presenter: Emma Seals | PharmD Candidate 2026 | The Ohio State University College of PharmacyCopyright Notice: By accessing this podcast, you understand and acknowledge that its contents and materials are the property of ACCP and the Emergency Medicine PRN. Further, the podcast, its contents and its materials are protected under United States and international copyright and trademark law. You understand that the podcast, its contents or materials are to be used only for personal or non-commercial purposes.Limitation of Liability; ACCP AND THE EMERGENCY MEDICINE PRN DISCLAIM ANY AND ALL LIABILITY OR RESPONSIBILITY FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR ANY OTHER DAMAGES, INCLUDING WITHOUT LIMITATION, LOSS OF PROFITS, ARISING OUT OF ANY USE OF, REFERENCE TO, RELIANCE ON, OR INABILITY TO USE THE PODCAST, ITS CONTENTS AND MATERIALS.Produced by Christian Kroll, PharmD, BCPS